An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab.

Trial Profile

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms CARE-MS Extension Study; CARE-MS II Extension Study
  • Sponsors Genzyme Corporation; Sanofi Genzyme
  • Most Recent Events

    • 28 Oct 2017 Results of analysis providing updated pregnancy outcomes in alemtuzumab-treated female patients from the clinical development program trials (NCT00050778, [NCT00530348, NCT00548405, NCT00930553, NCT02255656) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results assessing efficacy of alemtuzumab retreatment in pooled CARE-MS I and II patients who received third course of treatment during extension study presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 27 Oct 2017 Results at 5 years into the extension study were presented at the 7th Joint Meeting of the European and Americas Committees for Research and Treatment in Multiple Sclerosis (ECTRIMS-ACTRIMS), according to a Sanofi Genzyme media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top